HELP

Cybin Inc

• Reuters·03/27 14:16

  Cybin publishes corporate presentation; pipeline advances HLP003 in Phase 3 for adjunctive MDD and HLP004 targets GAD with positive Phase 2 data

• Reuters·03/18 14:47

  Cybin Inc. Publishes Corporate Presentation on HLP003 and HLP004 Serotonergic Agonist Programs for MDD and GAD

• TipRanks·03/12 14:25

  Psychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort

• TipRanks·03/12 12:26

  Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances

• Reuters·03/12 11:31

  Cybin’s Helus Pharma appoints Jill Conwell as Chief People Officer

• Reuters·03/12 11:30

  HELUS PHARMA STRENGTHENS EXECUTIVE TEAM WITH APPOINTMENT OF JILL CONWELL AS CHIEF PEOPLE OFFICER

• TipRanks·03/06 14:36

  Buy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026

• TipRanks·03/06 12:12

  Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), McKesson (MCK) and Cybin (HELP)

• Benzinga·03/05 17:05

  12 Health Care Stocks Moving In Thursday's Intraday Session

• TipRanks·03/05 16:16

  H.C. Wainwright Reaffirms Their Buy Rating on Cybin (HELP)

• Benzinga·03/05 15:38

  Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

• TipRanks·03/05 15:15

  Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results

• Seeking Alpha·03/05 13:18

  Helus posts mid-stage trial data for anxiety disorder therapy

• TipRanks·03/05 13:17

  Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety

• TipRanks·03/05 13:10

  Helus Pharma announces results in Phase 2 signal detection study of HLP004